An open label, phase 1 study to evaluate the safety, feasibility and immunogenicity of an allogeneic, cell-based vaccine (VIDIDENCEL) in high grade serous ovarian cancer patients after primary treatment (ALISON)
Phase 1 other active
Quick answer
An open label, phase 1 study to evaluate the safety, feasibility and immunogenicity of an allogeneic, cell-based vaccine (VIDIDENCEL) in high grade serous ovarian cancer patients after primary treatment (ALISON) for High grade serous ovarian cancer is a Phase 1 program (other) at Disc Medicine with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Disc Medicine
- Indication
- High grade serous ovarian cancer
- Phase
- Phase 1
- Modality
- other
- Status
- active